Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer

Journal:

The New England Journal of Medicine

Published:

2026-05-28

DOI:

10.1056/nejmoa2517729

Affiliations:

30

Authors:

29

Go to article

Institutions	Authors	Share
Jazz Pharmaceuticals PLC, United States of America (USA)	4.000000	0.14
BeOne Medicines, China	3.000000	0.10
University Hospitals Leuven (UZ Leuven), Belgium	1.000000	0.03
National Cancer Center Hospital East, Japan	1.000000	0.03
China Medical University Hospital (CMUH), Taiwan	1.000000	0.03
Hospital Regional Universitario de Málaga, Spain	1.000000	0.03
IRCCS National Cancer Institute (INT) Milan, Italy	1.000000	0.03
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.03
Yonsei Cancer Hospital, South Korea	1.000000	0.03
Kyungpook National University (KNU), South Korea	1.000000	0.03
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.03
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.03
Zhongshan Hospital, Fudan University, China	1.000000	0.03
Olivia Newton-John Cancer Wellness and Research Centre, Australia	1.000000	0.03
National Cancer Institute, Malaysia	1.000000	0.03
Catalan Institute of Oncology (ICO), Spain	1.000000	0.03
Centre Eugène Marquis (CEM), France	1.000000	0.03
Seoul National University Bundang Hospital (SNUBH), South Korea	1.000000	0.03
Liaoning Cancer Hospital and Institute, China	1.000000	0.03
Fiona Stanley Hospital (FSH), Australia	1.000000	0.03
Centrul de Oncologie Sf Nectarie Craiova, Romania	0.500000	0.02
Vall d'Hebron University Hospital (HUVH), ICS, Spain	0.500000	0.02
University of Medicine and Pharmacy Craiova (UMF Craiova), Romania	0.500000	0.02
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, China	0.500000	0.02
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	0.500000	0.02
Changzhi People's Hospital, China	0.500000	0.02
Changzhi Medical College, China	0.500000	0.02
Vall d'Hebron Research Institute (VHIR), HUVH ICS, Spain	0.250000	0.01
University of Vic - Central University of Catalonia (UVic-UCC), Spain	0.250000	0.01

Interested in Oncology and Carcinogenesis?